Adherex Technologies, Inc.

Patent issued for method of improving drug delivery to tumors

Published in Pharma Law Weekly, November 2nd, 2004

Adherex Technologies, Inc., (AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, announced that it has been issued U.S. Patent No. 6,797,807, entitled Compounds and Methods for Cancer Therapy.

The patent covers the use of the proprietary cancer therapeutic agents to improve drug delivery to tumors by preventing a cell adhesion protein, known as occludin, from forming cellular barriers within tumors. The patented method may also improve the ability of immune cells to infiltrate tumors.

Cancerous tumors have evolved sophisticated mechanisms for fighting off attempts to kill them, said Orest Blaschuk, PhD,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2004-11-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry